Compare ARLO & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARLO | CAPR |
|---|---|---|
| Founded | 2018 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2018 | 2011 |
| Metric | ARLO | CAPR |
|---|---|---|
| Price | $12.67 | $25.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $24.00 | ★ $44.63 |
| AVG Volume (30 Days) | ★ 1.2M | 805.2K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 145.16 | N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.29 | N/A |
| Revenue Next Year | $8.82 | $3.31 |
| P/E Ratio | $94.77 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.05 | $4.30 |
| 52 Week High | $19.94 | $40.37 |
| Indicator | ARLO | CAPR |
|---|---|---|
| Relative Strength Index (RSI) | 41.57 | 32.86 |
| Support Level | $11.94 | $21.56 |
| Resistance Level | $14.35 | $25.70 |
| Average True Range (ATR) | 0.49 | 1.16 |
| MACD | -0.04 | -0.26 |
| Stochastic Oscillator | 24.43 | 8.94 |
Arlo Technologies Inc is engaged in the provision of security and video monitoring solutions for homes and businesses. It combines a cloud infrastructure and mobile app with various smart connected devices to provide users with visibility, insight, and a means to help protect and connect in real-time with the people and things from any location with a Wi-Fi or a cellular connection. The company offers subscription services such as Arlo Secure, Arlo Total Security, and Arlo Safe, and several categories of smart security devices, including smart Wi-Fi and LTE-enabled cameras, video doorbells, floodlight cameras, and home security systems. Geographically, the company generates a majority of its revenue from the United States, followed by Spain, Sweden, and other countries.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.